Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Craig D. Blinderman

2 papers in the library · 73 citations · publishing 2020-2021

Papers

Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives

Journal of Palliative Medicine April 1, 2020 Yvan Beaussant, Justin J. Sanders, Zachary Sager et al. 39 citations

Experts in serious illness care and psychedelic research hold polarized views on psychedelic-assisted therapies for patients with serious illness, ranging from strong support for medical utility to reluctance due to risks such as delirium or worsening psychological distress. Research priorities focus on patients with clinically diagnosed psychosocial distress like depression, anxiety, or demoralization, though some roles extend beyond traditional medical diagnosis. Essential safety and efficacy guidelines are needed for integrating these therapies into existing care models. The study proposes a conceptual framework for such integration based on interviews with 17 experts from the United States and Canada.

Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness.

J Palliat Med April 13, 2021 Yvan Beaussant, James A. Tulsky, Benjamin Guérin et al. 34 citations

Researchers from palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies identified seven key opportunities for advancing research on psychedelic-assisted therapy for people with serious illness. Four opportunities relate to science and design: clarifying which conditions the therapy is indicated for, developing and refining therapeutic protocols, investigating how set and setting affect outcomes, and understanding mechanisms of action. Three opportunities concern institutional and societal drivers: education and certification for therapists, regulations and funding, and diversity and inclusion. Participants also noted epistemological limitations of the medical model for understanding psychedelics' therapeutic value.